B. Charpentier

B. Charpentier

Auto-generated profile, based on publicly available information

B. Charpentier

Department of Medicine, Division of Gastroenterology, Hepatology & Nutrition, University of Louisville School of Medicine, Louisville, KY, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2024 in Gut Microbes
Verified
Journal Article
Open access
PCPaula M. Chilton
Paula M. Chilton
SGSmita Ghare
Smita Ghare
BCBenjamin T. Charpentier
Benjamin T. Charpentier
SMScott A. Myers
Scott A. Myers
ARAakarsha V. Rao
Aakarsha V. Rao
SBShirish S Barve
Shirish S Barve
Alterations in the gut-microbiome-brain axis are increasingly being recognized to be involved in Alzheimer's disease (AD) pathogenesis. However, the functional consequences of enteric dysbiosis linking gut microbiota and brain pathology in AD progression remain largely undetermined. The present work investigated the causal role of age-associated temporal decline in butyrate-producing bacteria and butyrate in the etiopathogenesis of AD. Longitudinal metagenomics, neuropathological, and memory analyses were performed in the 3×Tg-AD mouse model. Metataxonomic analyses showed a significant temporal decline in the alpha diversity marked by a decrease in butyrate-producing bacterial communities and a concurrent reduction in cecal butyrate production. Inferred metagenomics analysis identified the bacterial acetyl-CoA pathway as the main butyrate synthesis pathway impacted. Concomitantly, there was an age-associated decline in the transcriptionally permissive acetylation of histone 3 at lysines 9 and 14 (H3K9/K14-Ac) in hippocampal neurons. Importantly, these microbiome-gut-brain changes preceded AD-related neuropathology, including oxidative stress, tau hyperphosphorylation, memory deficits, and neuromuscular dysfunction, which manifest by 17-18 months. Initiation of oral administration of tributyrin, a butyrate prodrug, at 6 months of age mitigated the age-related decline in butyrate-producing bacteria, protected the H3K9/K14-Ac status, and attenuated the development of neuropathological and cognitive changes associated with AD pathogenesis. These data causally implicate age-associated decline in butyrate-producing bacteria as a key pathogenic feature of the microbiome-gut-brain axis affecting the onset and progression of AD. Importantly, the regulation of butyrate-producing bacteria and consequent butyrate synthesis could be a significant therapeutic strategy in the prevention and treatment of AD.

1 February 2001 in Transplantation Proceedings
Verified
Journal Article
Closed access
CDC. Dumont
C. Dumont
ODO. Deas
O. Deas
CHC. Hebib
C. Hebib
ADAntoine DURRBACH
Antoine DURRBACH
FHFrançois Hirsch
François Hirsch
ASA. Senik
A. Senik

22 May 2001 in Transplantation Proceedings
Verified
Journal Article
Closed access
BCB Charpentier
B Charpentier
CHCh Hiesse
Ch Hiesse
ADAntoine DURRBACH
Antoine DURRBACH
MAM Ammor
M Ammor
FEF Von Ey
F Von Ey
FKF Kriaa
F Kriaa

1 April 2010 in Bulletin de l'Académie Nationale de Médecine
Verified
Journal Article
Closed access
FMFrançois-Bernard Michel
François-Bernard Michel
PAP. Ambroise-Thomas
P. Ambroise-Thomas
JCJ. Cambier
J. Cambier
BCB. Charpentier
B. Charpentier
DCD. Couturier
D. Couturier
CSC. Sureau
C. Sureau

15 July 2014 in Transplantation
Verified
Journal Article
Open access
BCB. Charpentier
B. Charpentier
CLC. Larsen
C. Larsen
JGJ. Grinyo
J. Grinyo
FMF. Muehlbacher
F. Muehlbacher
GBG. Blancho
G. Blancho
FVF. Vincenti
F. Vincenti

1 February 1999 in Transplantation Proceedings
Verified
Journal Article
Closed access
CHC Hiesse
C Hiesse
FKF Kriaa
F Kriaa
PEP Eschwege
P Eschwege
SBS Boubenider
S Boubenider
SMSophie Marchand
Sophie Marchand
BCB Charpentier
B Charpentier